Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by Domino55on Jan 27, 2022 1:42pm
216 Views
Post# 34367515

PMX Trial “Better than Expected”

PMX Trial “Better than Expected”I would have thought that this disclosure from Dr. Kellum might have been followed up with an updated Investor Presentation or NR by now. It has had no impact on the share price or demand for the stock. Except for a brief TFSA driven run up the SP has been stuck on hold, with declining volume, since the "trial update" was provided.

Not so hard to believe I guess, but still hard to believe.
<< Previous
Bullboard Posts
Next >>